Proven partnerships with industry pioneers and innovators
Delivering data-driven insights across the full discovery & development cycle
Target & biomarker discovery
Uncover key mechanisms, cellular context, and causal genes to identify & prioritise new therapeutic targets
Target validation
Assess human genetic evidence supporting target-indication pair to confidently advance high-value targets with strong causal evidence
On-target safety
Assess secondary on-target effects to shift safety-related attrition early and reduce costly late-stage failures
Indication selection
Prioritise or expand into new indications to maximise value of pipeline assets or marketed therapies
Omics-based stratification
Apply advanced methods and tools to develop population stratification approaches, enabling trial enrichment and precision medicine approaches
De-risk and accelerate discovery and development
Drug development remains challenging, with most candidates failing due to a lack of efficacy or unforeseen safety issues. Genetics provides a powerful means to address this. Genomics uses large-scale genomic data and machine learning to help identify and prioritise targets with causal evidence, assess safety risks earlier, stratify patient populations for greater therapeutic effect, and explore new indications for existing assets. This enables our partners to make faster strategic decisions with confidence.
Unmatched data scale and analytical power
We have curated one of the largest harmonised genotype–phenotype resources globally, comprising over 40,000 datasets and millions of analyses. Our platform integrates multi-omic datasets — including genomic, transcriptomic, proteomic, phenotypic, and real-world clinical data — enabling deeper insight into disease mechanisms and therapeutic opportunity.
This is supported by access to major public biobanks (e.g. UK Biobank, AllOfUs) alongside proprietary data, and powered by world-leading polygenic risk scores for disease prediction and patient stratification.
Largest and most diverse genotype-phenotype data resource enables the deepest insights into genetic drivers of diseases across all therapeutic areas
Scale of data delivers unmatched statistical power to uncover novel insights & drive high-confidence decisions
Private and proprietary data can be integrated into data platform in compliance with stringent infosec protocols
Tailored support across the pipeline
Genomics supports partners across the full R&D cycle — from novel target discovery to indication expansion and clinical trial design and rescue. Our genetics-first approach informs critical decisions on efficacy, safety, and patient stratification.
All programmes are built on our proprietary multi-omic platform and tailored to align with your strategic goals. Whether validating assets, uncovering new targets, or refining development plans, we deliver evidence-based insights to reduce risk and accelerate progress.
1
2014 report by Tufts Center for the Study of Drug Development (CSDD)
2
BIO New Clinical Development Success Rates 2011-2020 Report
3
Pfizer review of PTRS including their own benchmarks + MIT review across TAs with and without biomarkers (Table 3 - overall rates from FIH to approval with / without biomarkers 5.7%) https://www.sciencedirect.com/science/article/pii/S1359644621005444 & https://academic.oup.com/biostatistics/article/20/2/273/4817524?login=false#200808396
4
Nelson et al. (2015) Nature Genetics
Collaborate with us
We act as scientific partners to help integrate human genetics into drug discovery and development. Whether identifying new targets, evaluating clinical-stage assets, or refining development strategies, Genomics delivers customised, data-driven approaches tailored to your strategic goals. Together we can accelerate drug discovery and advance population health to help people live longer, healthier lives.
Get in touch
